Amgen shares hit after analysts expose buried FDA trial halt

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 13, 2019 at 11:22 AM.

  1. #1 cafead, Sep 13, 2019 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,268
    Likes Received:
    3
    via Thursday, Amgen posted what appeared to be a fairly innocuous update about its drug Kyprolis and other pipeline assets, but a deeper read turned up a nasty surprise.

    About midway through its release, the U.S. biopharma revealed matter-of-factly that a phase 1 dose escalation clinical trial for its drug AMG 397, an oral small molecule MCL1 inhibitor, in blood cancers has been hit with a clinical hold.

    article source
     
    Quote

Reply to Thread